Skip to main content

Table 5 Priorities stratified by stakeholder role

From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis

Variable Aggregate Clinicians Policy Makers Advocates Chi-squared p-value
  Coef ( SE ) Coef ( SE ) Coef ( SE ) Coef ( SE )  
Monitoring at-risk populations 13.75*** 14.76*** 14.58*** 8.33* 0.28
  (1.5) (2.0) (2.6) (3.6)  
Risk Assessment 5.42*** 5.73** 2.92 8.33* 0.47
  (1.3) (1.6) (2.7) (3.6)  
Access to treatments 5.21*** 4.34* 6.25* 6.94 0.76
  (1.4) (1.7) (3.6) (3.6)  
National guidelines 8.96*** 9.55*** 7.08* 9.72** 0.79
  (1.4) (1.7) (3.3) (3.6)  
Research infrastructure 3.96** 5.03** −1.25 8.33* 0.08
  (1.4) (1.6) (2.9) (3.3)  
Centers of excellence 6.86*** 7.81*** 4.58 6.94 0.66
  (1.5) (1.9) (3.0) (3.9)  
Multidisciplinary management 8.33*** 9.20*** 7.92** 5.56 0.52
  (1.4) (2.0) (2.3) (2.5)  
Clinician education 11.04*** 11.28*** 8.75** 13.89*** 0.35
  (1.3) (1.9) (2.4) (2.5)  
Public awareness 8.13*** 9.20*** 3.75 11.11** 0.15
  (1.4) (1.8) (2.5) (3.8)  
Transplantation infrastructure 0.42 1.56 −2.92 1.39 0.47
  (1.5) (2.1) (3.1) (3.6)  
Measuring social burden 5.21*** 3.3 8.75** 6.94 0.25
  (1.4) (1.6) (3.0) (4.8)  
  1. *p<0.05, **p<0.01, ***p<0.001, model R 2 =.287.
\